American Journal of Clinical Dermatology

, Volume 14, Issue 4, pp 261–272

Immunotherapy for the Management of Advanced Melanoma: The Next Steps

Authors

  • Dragoslav Zikich
    • Ella Institute for Melanoma, Sheba Medical Center
  • Jacob Schachter
    • Ella Institute for Melanoma, Sheba Medical Center
    • Ella Institute for Melanoma, Sheba Medical Center
    • Department of Clinical Microbiology and Immunology, Sackler School of MedicineTel Aviv University
Review Article

DOI: 10.1007/s40257-013-0013-0

Cite this article as:
Zikich, D., Schachter, J. & Besser, M.J. Am J Clin Dermatol (2013) 14: 261. doi:10.1007/s40257-013-0013-0

Abstract

Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.

Copyright information

© Springer International Publishing Switzerland 2013